Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Mar 11, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Natera and BGI Genomics said today that they have signed a $50 million partnership to commercialize Natera's circulating tumor DNA Signatera minimal residual disease (MRD) test in China and to develop reproductive health tests in "select markets," all using BGI's sequencing technology and instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
06
Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

What's Popular?

In Sequencing

  1. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  2. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  3. C2i Genomics Acquires Sequencing Lab QNA Dx

  4. Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.